categor
continu
variabl
compar
use
fisher
exact
test
wilcoxonrank
sum
test
respect
primari
outcom
mortal
assess
visual
use
kaplanmei
curv
multivari
cox
proport
hazard
final
multivari
cox
proport
hazard
model
incorpor
characterist
p
valu
bivari
analysi
administr
oral
rbv
forc
model
proport
hazard
assumpt
visual
assess
use
plot
scale
schoenfeld
residu
time
propens
analysi
perform
also
control
confound
creat
propens
score
nonparsimoni
logist
regress
model
incorpor
measur
baselin
characterist
sex
race
transplant
type
isi
score
site
infect
time
transplant
gvhd
steroid
use
nosocomi
infect
statu
creat
model
probabl
oral
rbv
treatment
propens
score
use
gener
invers
probabl
treatment
weight
iptw
subsequ
iptw
cox
proport
hazard
model
progress
uri
lri
assess
among
patient
treat
uri
stage
use
finegray
compet
risk
model
treat
death
compet
risk
progress
lri
tradit
multivari
model
iptw
compet
risk
model
construct
progress
lri
mortal
assess
previous
publish
isi
risk
categori
identifi
singl
group
highest
risk
classif
regress
tree
cart
analysi
use
identifi
isi
score
predict
mortal
progress
lri
mortal
compar
cartidentifi
low
highrisk
patient
data
collect
use
redcap
electron
data
captur
tool
statist
analys
perform
use
stata
version
statacorp
colleg
station
texa
sa
jmp
pro
version
sa
institut
cari
north
carolina
cart
analysi
identifi
isi
signific
predictor
mortal
sensit
specif
area
receiv
oper
curv
found
among
patient
treat
aerosol
oral
rbv
patient
isi
similar
rate
progress
lri
vs
mortal
vs
mortal
vs
tabl
supplementari
tabl
patient
isi
higher
mortal
rate
isi
rate
remain
similar
group
mortal
aerosol
oral
mortal
aerosol
oral
patient
demograph
clinic
characterist
stratifi
mortal
present
tabl
outcom
shown
tabl
patient
die
within
day
like
receiv
corticosteroid
survivor
vs
p
lymphopenia
vs
p
nosocomi
infect
vs
p
highrisk
isi
score
vs
p
differ
note
percentag
patient
receiv
oral
rbv
initi
treatment
survivor
nonsurvivor
p
signific
predictor
mortal
multivari
cox
proport
hazard
model
nosocomi
infect
adjust
hazard
ratio
ahr
confid
interv
ci
p
lri
diagnosi
ahr
ci
p
haploident
transplant
ahr
ci
p
oral
administr
predict
mortal
ahr
ci
p
figur
supplementari
figur
complet
result
univari
multivari
cox
proport
hazard
model
depict
tabl
iptw
cox
proport
hazard
model
treatment
oral
rbv
signific
predictor
mortal
hr
ci
p
ninetyday
mortal
significantli
lower
oral
rbv
recipi
compar
aerosol
rbv
via
multivari
cox
proport
hazard
model
ahr
ci
p
howev
signific
differ
observ
iptw
model
hr
ci
p
signific
predictor
mortal
gener
reflect
underli
comorbid
includ
relaps
diseas
highrisk
transplant
type
supplementari
figur
full
demograph
clinic
characterist
patient
multivari
cox
proport
hazard
model
mortal
present
supplementari
tabl
patient
lri
present
differ
mortal
oral
aerosol
therapi
mortal
oral
vs
aerosol
p
mortal
oral
vs
aerosol
p
fiftytwo
patient
treat
rbv
uri
stage
progress
oral
rbv
signific
predictor
progress
lri
tradit
multivari
finegray
compet
risk
model
adjust
subhazard
ratio
shr
ci
p
figur
iptw
finegray
compet
risk
model
shr
ci
p
full
finegray
compet
risk
model
present
supplementari
tabl
icu
transfer
rate
need
mechan
ventil
oral
vs
aerosol
rbv
patient
similar
icu
transfer
vs
p
mechan
ventil
vs
p
hemoglobin
level
similar
aerosol
oral
group
baselin
day
day
newonset
grade
anemia
classifi
common
terminolog
criteria
advers
event
supplementari
tabl
studi
hct
recipi
rsv
infect
similar
mortal
progress
lri
treat
aerosol
oral
rbv
despit
use
multipl
statist
method
includ
propens
model
signal
increas
efficaci
aerosol
rbv
observ
moreov
oral
rbv
associ
increas
rate
grade
greater
anemia
find
suggest
oral
rbv
may
safe
effect
altern
aerosol
rbv
treatment
rsv
hct
recipi
import
implic
hct
program
given
signific
aerosol
rbv
cost
treatment
option
rsv
infect
hct
recipi
limit
rbv
commonli
use
pharmaceut
agent
market
formul
aerosol
oral
intraven
intraven
formul
approv
us
food
drug
administr
fda
routin
avail
clinic
use
although
aerosol
rbv
fdaapprov
treatment
rsv
children
sever
retrospect
studi
suggest
treatment
aerosol
rbv
associ
reduc
mortal
hct
recipi
thu
broadli
use
indic
due
teratogen
aerosol
rbv
must
administ
inpati
via
scaveng
tent
daili
administr
time
challeng
patient
provid
cost
aerosol
rbv
increas
roughli
per
day
place
cost
treatment
cours
stagger
result
aerosol
rbv
longer
viabl
mani
institut
leav
oral
rbv
avail
treatment
institut
aerosol
rbv
remain
unrestrict
given
widespread
public
increas
cost
therapi
eas
oral
administr
shift
use
toward
oral
rbv
occur
natur
last
rsv
season
howev
pauciti
data
oral
rbv
rsv
hct
recipi
limit
widespread
accept
equival
altern
aerosol
rbv
prior
studi
oral
rbv
hct
patient
provid
limit
mix
result
knowledg
largest
studi
date
compar
outcom
oral
aerosol
rbv
rsv
hct
recipi
thirtyday
mortal
rate
similar
group
mortal
significantli
lower
recipi
oral
rbv
multivari
cox
proport
hazard
model
sever
signific
predictor
mortal
reflect
underli
highrisk
transplant
relaps
underli
malign
like
reflect
degre
residu
select
bia
rather
true
efficaci
signal
although
number
patient
high
risk
isi
rel
low
indic
increas
mortal
observ
patient
treat
oral
rbv
addit
mortal
oral
aerosol
rbv
patient
lri
suggest
oral
formul
effect
aerosol
therapi
lower
respiratori
diseas
patient
uri
similar
progress
rate
lri
regardless
treatment
oral
aerosol
rbv
find
robust
standard
finegray
compet
risk
model
propens
analysi
mortal
patient
high
risk
progress
appear
addit
risk
treat
oral
rbv
find
contrast
casey
et
al
evalu
patient
treat
oral
rbv
rsv
infect
allogen
hct
uri
cohort
uri
progress
document
everi
case
patient
die
respiratori
failur
howev
patient
treat
median
day
follow
transplant
high
risk
progress
regardless
treatment
wherea
cohort
includ
entir
posttransplant
spectrum
studi
includ
compar
group
receiv
rbv
limit
data
compar
oral
rbv
therapi
fiftysix
patient
univers
heidelberg
treat
oral
rbv
rsv
outbreak
hct
recipi
receiv
oral
rbv
multivari
analysi
identifi
treatment
rbv
protect
factor
fatal
outcom
p
marcelin
et
al
assess
oral
rbv
administ
immunocompromis
patient
rsv
infect
includ
recipi
hct
patient
death
attribut
rsv
recent
gorcea
et
al
examin
effect
oral
rbv
treatment
rsv
allogen
hct
recipi
patient
highrisk
isi
score
patient
escal
aerosol
therapi
median
month
followup
patient
aliv
death
rsv
relat
institut
aerosol
rbv
commonli
dose
intermitt
g
hour
time
per
day
two
common
dose
strategi
oral
rbv
use
fix
dose
mg
everi
hour
load
dose
mgkg
follow
mgkgday
divid
dose
adjust
renal
dysfunct
dose
use
base
report
literatur
howev
optim
dose
rbv
rsv
establish
similarli
optim
durat
therapi
unknown
substanti
heterogen
practic
report
assess
optim
dose
durat
oral
rbv
area
ongo
research
group
strength
studi
includ
comparison
outcom
rbv
formul
diseas
sever
control
mani
cofound
addit
size
institut
inclus
consecut
rsv
season
allow
inclus
larg
number
patient
differ
hct
type
risk
strata
includ
relaps
diseas
howev
studi
limit
singlecent
studi
evalu
hct
recipi
therefor
generaliz
nontranspl
recipi
institut
may
limit
studi
includ
lowrisk
hct
patient
isi
may
requir
treatment
rbv
howev
group
compris
small
portion
cohort
similarli
number
patient
highrisk
group
isi
low
cohort
thu
impact
oral
rbv
highrisk
patient
need
studi
last
studi
retrospect
natur
significantli
patient
lymphopenia
aerosol
group
although
found
independ
associ
mortal
multivari
analysi
tabl
summari
studi
provid
evid
support
use
oral
rbv
place
aerosol
rbv
treatment
rsv
infect
hct
recipi
includ
patient
high
risk
progress
mortal
find
still
requir
valid
prefer
via
prospect
trial
mani
institut
alreadi
adopt
practic
find
may
address
remain
concern
use
oral
instead
aerosol
rbv
hct
patient
